TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35272897
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received standard IO antibiotic injection
Study: 33244562
Drug: MCP® BCMC®
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP® BCMC® strains (administered twice daily)
Study: 33539946
Drug: Chemotherapy (topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (topotecan or amrubicin)
Study: 33168839
Drug: Laxative immediately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative immediately followed by Clostridium butyricum (CB) administration for 2 weeks (LP)
Study: 33168839
Drug: Laxative, interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative, interval of 2 weeks and CB administration for 2 weeks (L2P)
Study: 33168839
Drug: CB administration
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB administration for 2 weeks (P)
Study: 33821332
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (8000 IU daily)
Study: 33761932
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of transcranial pulsed current stimulation (tPCS) at 400 Hz, 1 mA and transcutaneous electrical nerve stimulation (TENS) at 400 Hz, max 10 mA for 30 min, followed by 30 min of physiotherapy five times per week for 12 weeks.
Study: 36446452
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and adjuvant chemotherapy
Study: 35403245
Drug: Veliparib in
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib in combination with carboplatin/paclitaxel (120 mg twice daily)
Study: 35809704
Drug: β‐caryophyllene (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐caryophyllene (100 mg/daily with meal)
Study: 32535732
Drug: IL-6 inhibitors
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 inhibitors (tocilizumab, sarilumab, siltuximab)
Study: 32535732
Drug: IL-6 inhibitors
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 inhibitors (tocilizumab, sarilumab)
Study: 36220198
Drug: Incentivized lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentivized lifestyle intervention program with stepwise addition of metformin
Study: 33471963
Drug: Telephone-delivered adherence
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered adherence therapy (8 weekly 30-min sessions)
Study: 36106493
Drug: Intranasal isotonic
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal isotonic saline (Group C)
Study: 36106493
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 0.5 μg kg-1 (Group D0.5)
Study: 36106493
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1.0 μg kg-1 (Group D1.0)
Study: 36106493
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1.5 μg kg-1 (Group D1.5)
Study: 36106493
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2.0 μg kg-1 (Group D2.0)
Study: 36106493
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (ED95)
Study: 34225282
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued to receive anticholinergic drugs for 90 days
Study: 32350762
Drug: SSIDB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSIDB with 2 ml of 1% lidocaine
Study: 32350762
Drug: SSIDB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSIDB with 1 ml of 1% lidocaine
Study: 33903656
Drug: PAM intervention
Normalized name: 2-PAM
DrugBank: Pralidoxime (DB00733)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAM intervention as an adjunct to usual care
Study: 33721863
Drug: Low Oral
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Oral Health Literacy (OHL) score
Study: 36087612
Drug: PrEP adherence
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP adherence measured by plasma tenofovir concentrations of at least 40 ng/mL
Study: 35584248
Drug: SABER-Bupivacaine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABER-Bupivacaine 5 mL
Study: 35584248
Drug: Placebo 5
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mL
Study: 35584248
Drug: Bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride 20 mL
Study: 34405362
Drug: Streptokinase (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (50,000 IU in 100 ml normal saline)
Study: 34405362
Drug: 3% H2O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% H2O2 (3% H2O2 in 100 ml normal saline in 1:10 dilution)
Study: 33686610
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg single dose with 150 mg Mg2+
Study: 33686610
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg multiple doses with 75 mg Mg2+
Study: 32084592
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) plus standard care (systemic anticoagulation and/or antiplatelet therapy)
Study: 34119535
Drug: Ranibizumab 100
Normalized name: ranibizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 100 μg/ml
Study: 34119535
Drug: Aflibercept 400
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept 400 μg/ml
Study: 34119535
Drug: Conbercept 100
Normalized name: Conbercept
DrugBank: Conbercept (DB12460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept 100 μg/ml
Study: 34119535
Drug: 3‐MA or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐MA or CQ (autophagy inhibitors)
Study: 32521132
Drug: Givosiran (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran (2.5 mg/kg, subcutaneous, monthly for 6 months)
Study: 34845313
Drug: 100 µg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg of vitamin K2 (MK‐7)
Study: 34845313
Drug: 10 µg of
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 µg of native vitamin D
Study: 34845313
Drug: 100 µg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg of vitamin K2 (MK‐7) and 10 µg of native vitamin D
Study: 33686887
Drug: SilvrSTAT Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SilvrSTAT Gel dressing
Study: 32326757
Drug: Modified relative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified relative dose response (MRDR) test
Study: 33248910
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration nano-hydroxyapatite (nHAP) applied for 2 to 3 minutes daily for 10 days
Study: 32816944
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg infusion with cisplatin and gemcitabine
Study: 32816944
Drug: Bevacizumab 2.5
Normalized name: Bevacizumab 2.5 MG/0.1 ML Intraocular Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 2.5 mg/kg infusion with cisplatin and gemcitabine
Study: 32816944
Drug: Sunitinib 12.5
Normalized name: sunitinib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 12.5 mg/day with cisplatin and gemcitabine
Study: 32816944
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg/day with cisplatin and gemcitabine
Study: 32816944
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine chemotherapy without anti-VEGF therapy
Study: 35242594
Drug: Blended cognitive-behavioral
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive-behavioral therapy (CBT)
Study: 35242594
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral therapy (CBT)
Study: 35157993
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment after relapse
Study: 33838224
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus TPE (n=43)
Study: 33838224
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=44)
Study: 32687161
Drug: RTS,S/AS01B or
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01B or RTS,S/AS01E (3 doses on a 0-1-7-month schedule, with the final 1 or 2 doses being fractional)
Study: 32687161
Drug: RTS,S/AS01E (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E (2 doses: 1 full at month 0 and 1 fractional at month 7)
Study: 33151132
Drug: Saffron group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron group (received routine care plus capsule of saffron 400 mg/day, 200 mg twice per day)
Study: 34259401
Drug: Estazolam tablets
Normalized name: Estazolam Tablets
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam tablets (1 mg)
Study: 32255785
Drug: PBM in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM in the sublingual region
Study: 35237033
Drug: Liraglutide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3.0 mg, s.c.)
Study: 32331064
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SPN-812
Study: 33836772
Drug: Mass Screening
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Screening and Treatment (MST) intervention
Study: 34085115
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg/day)
Study: 36093566
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg selenium as selenium-enriched yeast daily
Study: 36093566
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg selenium as selenium-enriched yeast daily
Study: 36093566
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg selenium as selenium-enriched yeast daily
Study: 36093566
Drug: 100, 200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100, 200, or 300 μg selenium as selenium-enriched yeast daily
Study: 33609973
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) in high-risk patients (34.4%, n = 166)
Study: 33609973
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) in low-risk patients (36.5%, n = 203)
Study: 36145126
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B1 and mecobalamin, artificial tears
Study: 33351971
Drug: HTL0018318 (1–35
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0018318 (1–35 mg)
Study: 32275025
Drug: Propofol-dexmedetomidine continuous
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-dexmedetomidine continuous infusion
Study: 32275025
Drug: Propofol continuous
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol continuous infusion
Study: 32359348
Drug: Butorphanol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol at the ED95 dose (9.07 μg/kg)
Study: 32359348
Drug: Sufentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil at the ED95 dose (0.1 μg/kg)
Study: 34590159
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose control (CC group) maintaining glycaemia below 180 mg/dL.
Study: 35230488
Drug: delgocitinib ointment
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: delgocitinib ointment 30 mg/g (n = 20)
Study: 35230488
Drug: vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle ointment (n = 11)
Study: 33352007
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program combined with manual therapy (mobilization group)
Study: 33352007
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy only (control group)
Study: 35690093
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose injection
Study: 35690093
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride) injection
Study: 36123185
Drug: Freehand group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freehand group (screw channel preparation based on panoramic radiographs without a drilling guide)
Study: 34045114
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion policy (packed cells when Hemoglobin < 8 g/dL)
Study: 34045114
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion policy (packed cells when Hemoglobin < 10 g/dL)
Study: 35413602
Drug: Pequi oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pequi oil nanoencapsulated gel (PeONC)
Study: 35749267
Drug: MAX intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAX intervention (problem-solving therapy with energy conservation education)
Study: 33415866
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy (once daily for 14 days)
Study: 33415866
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (western medicine)
Study: 34954870
Drug: Digital informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital informed consent (DIC) using hyperrealistic simulation on a tablet device
Study: 36167477
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% 30 mL on each side
Study: 33393805
Drug: Cue detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue detection and combination conditions
Study: 36207643
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered through a target-controlled infusion device programmed with the covariates model, plasma target concentrations between 2 and 5 μg.mL−1.
Study: 34533825
Drug: 20 opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 opioid pills (Group 1)
Study: 34533825
Drug: 40 opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 opioid pills (Group 2)
Study: 33039944
Drug: Ocrelizumab 600
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 600 mg administered over 3.5 hours (conventional duration)
Study: 33039944
Drug: Ocrelizumab 600
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 600 mg administered over 2 hours (shorter duration)
Study: 33963479
Drug: β ‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: β ‐glucan (200 mg daily)
Study: 33675850
Drug: Methotrexate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (25 mg weekly oral)
Study: 33675850
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil (1.5 g twice daily oral)
Study: 32651955
Drug: PT20 (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT20 (400, 800, 1600 or 3200 mg)
Study: 39577033
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment
Study: 32093617
Drug: Sumatriptan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (4 mg)
Study: 32556659
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + nutraceutical agent (test group)
Study: 34459089
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural intervention (CBT) with compassion-focused therapy methods, delivered in six sessions.
Study: 33077017
Drug: 3% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic saline (HYPER) infusion (0.1 ml/kg per min for 2 hours)
Study: 33964853
Drug: Wolfberry (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wolfberry (15 g/d)
Study: 33469316
Drug: Tezepelumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (all doses)
Study: 36216004
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet of less than 1500 mg/day
Study: 33932589
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg, intravenously, Q 12 h) for the first 5 postoperative days
Study: 33932589
Drug: On-demand opioid
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand opioid analgesics (pethidine or morphine) postoperatively
Study: 35829974
Drug: Delicate pulsed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delicate pulsed light (DPL) combined with low-dose oral isotretinoin (10–20 mg/day)
Study: 35829974
Drug: Isotretinoin monotherapy
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin monotherapy
Study: 33742786
Drug: HBM9161 340
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 340 mg
Study: 33742786
Drug: HBM9161 510
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 510 mg
Study: 33742786
Drug: HBM9161 680
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 680 mg
Study: 35783528
Drug: Xinjia Xuanbai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinjia Xuanbai Chengqi granules (XJXBCQ) combined with conventional treatment (budesonide suspension)
Study: 35783528
Drug: Xinjia Xuanbai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinjia Xuanbai Chengqi granules (XJXBCQ) and budesonide suspension (full dosage)
Study: 35783528
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (budesonide suspension and placebo)
Study: 32914639
Drug: Enhanced upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced upper limb therapy programme (36 one-hour sessions over 12 weeks, including 45 minutes of face-to-face therapy)
Study: 32434291
Drug: Nebulized dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized dexmedetomidine (1 µg/kg in 3‐4 ml of 0.9% saline)
Study: 32434291
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (3‐4 ml)
Study: 35065683
Drug: High-titre RV3-BB
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-titre RV3-BB vaccine
Study: 35065683
Drug: Mid-titre RV3-BB
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mid-titre RV3-BB vaccine
Study: 35065683
Drug: Low-titre RV3-BB
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-titre RV3-BB vaccine
Study: 35065683
Drug: High-titre RV3-BB
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-titre RV3-BB vaccine (infant schedule)
Study: 35065683
Drug: Overall vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall vaccine take
Study: 33423986
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (10 mg/kg in 100 ml isotonic saline)
Study: 33423986
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ml isotonic saline)
Study: 34520052
Drug: Anti-PD-1-based first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-PD-1-based first-line treatment
Study: 35157236
Drug: HSK3486 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 0.4 mg/kg
Study: 33100184
Drug: Contact-control intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact-control intervention (CC)
Study: 33746195
Drug: Papilocare, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papilocare, a Coriolus versicolor-based vaginal gel
Study: 35170523
Drug: Parent-reported use
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-reported use of topical corticosteroids
Study: 35710091
Drug: Calf muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf muscle exercise training (ETC) in addition to compression therapy (CT)
Study: 35710091
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) in addition to compression therapy (CT)
Study: 33957371
Drug: Rasburicase 1.5
Normalized name: rasburicase 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasburicase 1.5 mg
Study: 33957371
Drug: Rasburicase 3
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rasburicase 3 mg